Introduction
Lung cancer is known to arise in relation to pulmonary scars (Matthews 1974) ; more recently an excess risk has been reported of developing bronchogenic carcinoma in patients with cryptogenic fibrosing alveolitis (Turner-Warwick et al., 1980) . The distribution of the histological types of carcinoma is similar to that of patients without fibrosis (Stack, Choo-Kang and Heard, 1972; Turner-Warwick et al., 1980) . Palliative megavoltage radiotherapy given for lung carcinoma is not usually associated with noticeable pulmonary fibrosis when conventional doses are prescribed (Weir and Michaelson, 1971) . The prognosis of patients with small cell lung cancer has appreciably improved with modern chemotherapy (Livingston, 1980) . It is being increasingly recognized, however, that some cytotoxic agents may themselves cause lung damage (Collis, 1980) .
Corticosteroids have been extensively used with variable efficacy in the treatment of cryptogenic fibrosing alveolitis. Other immunosuppressive agents including cytotoxic drugs (azathioprine, cyclophosphamide) are under investigation as potential treatment for fibrosing alveolitis (Crystal et al., 1976; Plowman and Stableforth, 1977) .
An interesting paradox then occurs when chemotherapy is given to patients with small cell lung cancer and co-existing cryptogenic fibrosing alveolitis. The chemotherapy could aggravate the alveolitis or conversely retard or improve the fibrotic change.
The clinical course of two patients with small cell lung cancer and cryptogenic fibrosing alveolitis treated with chemotherapy and irradiation is described. 
Treatment
The treatment protocol consisted of two i.v. bolus injections of methotrexate 100 mg/M2, no folinic acid being required, at a 2-week interval. Mediastinal irradiation (4MV) encompassing obvious tumour started the day after the 2nd injection of methotrexate; 8 daily fractions by parallel pair fields (12 x 10 cm) to 3100 cGy tumour dose was given.
Two weeks after the final fraction of radiotherapy escalating high-dose cyclophosphamide was administered i.v. at 1-5 g/m2 proceeding to 2 5 g and 3.5 g/m2 at 3-week intervals. Since the third dose of cyclophosphamide no further chemotherapy has been given.
The pulmonary function studies (Table 1) showed no marked change when the pre-treatment values were compared with the test values, obtained after irradiation (but before cyclophosphamide), one month and four months after the last cyclophosphamide injection. Examination of chest radiographs showed no marked increase in the fibrosis (outside the radiotherapy field) when the pre-treatment films were compared with the films taken 4 months after the last administration of cyclophosphamide (Figs 1 & 2) .
Discussion
Chemotherapy for small cell lung cancer is now an established practice (Livingston, 1980) . Although the risk of lung cancer is increased in patients with cryptogenic fibrosing alveolitis (Turner-Warwick et al., 1980) , there are no reports of the effect of anti-cancer therapy upon the alveolitis. The diagnosis of cryptogenic fibrosing alveolitis in the two patients was based upon characteristic clinical and radiological features. The initial pulmonary function also indicated a fibrosing disorder; lung biopsy for histological confirmation was not considered indicated.
Lung damage following cytotoxic therapy was (Collis, 1980) . Methotrexate lung damage has been noted over a wide dose-range including 100 mg/M2 used in the present study. The incidence is independent of dose or duration of treatment and enhancement of radiation pneumonitis has not been reported (Collis, 1980) . Cyclophosphamide-induced lung damage has been described in patients receiving continuous low-dose therapy (Willson, 1978) .
The two patients did not experience exacerbation of any symptoms suggestive of drug induced lung damage. There was some increase in shadowing on the chest radiograph but this occurred within the irradiated field and was unassociated with any increase in lung markings elsewhere. The pulmonary function tests in the two patients showed no marked change with treatment; in particular there was no obvious increase in the restrictive ventilatory defect nor in the diffusion defect that is associated with radiation lung damage. It is interesting that even the high doses of cyclophosphamide comparable to those used in bone marrow transplantation were not associated with obvious pulmonary damage and a relationship of dose to lung toxicity was not obvious. In other patients treated for bronchogenic carcinoma, an increase in vital capacity, residual volume and FEV1 (particularly if at presentation marked airways obstruction was evident) is commonly found soon after the start of irradiation followed by a slow decline with ultimate stabilization at or just below pretreatment values; the diffusing capacity for CO usually decreases after irradiation in the majority of patients (Bousky, Helgasan, and North, 1970; Weir and Michaelson, 1971) . Although the patients' symptoms improved following tumour regression there was some decrease in the diffusing capacity for CO but the lung volumes in the two patients were largely unchanged, probably representing the restriction imposed by the pre-existing lung fibrosis. Unfortunately there is no firm correlation between radiography, pulmonary function studies and symptoms in patients with cryptogenic fibrosing alveolitis (Crystal et al., 1976) , and a similar problem is present in the serial follow-up of patients receiving agents potentially toxic to the lungs.
Clinical symptoms attributable to a radiation lung reaction in patients irradiated for bronchogenic carcinoma are unusual but the radiographic evidence of fibrosis increases with time, individual susceptability being a marked feature (Deeley, 1967) . No convincing evidence exists in humans that a reaction occurs in unexposed areas of irradiated lung (Weir and Michaelson, 1971) . There is no definite clinical evidence of a harmful interaction on lung tissue, between methotrexate and cyclophosphamide and irradiation, although this is not so for other cytotoxic drugs particularly in the case of the antitumour antibotics (Phillips and Fu, 1976 ).
An attempt has been made to improve the clinical course of patients with cryptogenic fibrosing alveolitis, in which the average untreated survival is 4 years, by deliberate immunosuppression, with antimetabolites (Crystal et al., 1976) . Plowman and Stableforth (1977) described improvement with cyclophosophamide in a patient with fibrosing alveolitis which was progressing despite steroids. In the present two patients, no improvement in lung function studies or chest radiographs as regards the pre-existing fibrosis was evident: the improvement in the patients' symptoms was considered to be a result of tumour regression. The scheduling of the intermittent chemotherapy in the present report would, however, be less immunosuppressive (Hersh, 1974) and possibly, therefore, less effective in controlling the alveolitis than the continuous administration described by Plowman and Stableforth (1977) .
It would seem reasonable that pre-existing lung disease would reduce the tolerance of the lung to irradiation and drug toxicity, but there was no evidence of untoward toxicity in the present two patients with small cell lung cancer and cryptogenic fibrosing alveolitis. There is no apparent contraindication to the use of intensive chemotherapy and radiotherapy in this clinical situation.
